Immuron Ltd — Regulatory Filings 2004

Dec 1, 2004

December $2^nd$ , 2004

Company Announcement Office Australian Stock Exchange Ltd (ASX) 4^th Floor, 20 Bridge Street Sydney NSW 2000

Dear Sir/Madam,

Anadis Ltd is pleased to advise that as part of our continuing marketing drive of our first research based product "Travelan" the following pamphlet was included in the November edition of the Australian Doctor newsletter – sent to Victorian GP's only at this time.

"The first product proven to reduce the risk of Travellers' Diarrhoea, rather than just treating the symptoms"

Travelan is now available in most Victorian pharmacies and a prominent product promotional display has been placed in the airport pharmacy window at Melbourne's Tullamarine airport.

Travelan will be officially launched nationally towards the end of the 1^st quarter 2005, although Travelan will be available in some interstate pharmacies well before this time, due to pharmacist and distributor demand.

For more information please contact: Steven Skorobogaty - General Manager Email: steven.s@anadis.com.au or Arie Nudel - Investor Relations Email: arie.n@anadis.com.au Tel: +61 3 9358 6388 Fax: +61 3 9358 6399

TEYQ GT REDUCES THE RISK OF TRAVELLERS' DIARRHOEA

Travellers' Diarhoea (TD) is the number one health problem in international travel in terms of frequency and economic impact.

Current management of TD is based on the relief of symptoms and re-hydration.

Travelan, a colostrum based product from Anadis, has been proven to actually reduce the risk of TD rather than just treating the symptoms.

Natural active ingredient

The active ingredient of Travelan is bovine colostrum powder (BCP) collected from Australian dairy cows immunised with a patented vaccine. As a result of our immunisation progam, this product contains very high levels of specific antibodies, against selected surface

V Clinically Proven V Natural Each capter contains Bonine Colosinum Powder 200mg

antigens from the common strains of Enterotoxigenic E.coli (ETEC), a common bacterial cause of TD.

How does Travelan work?

Using patented technology, Travelan works against bacteria as they enter the body, preventing them from attaching to the intestinal walls and thereby neutralising their ability to cause TD and its associated symptoms.

Photographic Evidence

ETEC strain H10407 adhering to differentiated Caco-2 cell line (colon carcinoma), used as a model of intestinal epithelium

Inhibition of adherence of H10407 to Caco-2 ceil line in the presence of 500µq/ml hyperimmune colostrum

40 x magnification, Phase-contrast, Giemsa stain

Target Market

Anyone travelling for any reason outside their native environment, including business and leisure travellers, honeymooners and military personnel. Chances of getting TD increase markedly in certain areas such as South and Latin America; Africa; Middle East; Asia and the Indian Sub-Continent. Areas with poor sanitation $-$ in particular of the water $supply - are especially high-risk.$

Dosage

Travelan is convenient and easy to take, one tablet prior to meals provides targeted action.

Results of the Clinical Trials

Travelan underwent stringent double-blinded, placebo-controlled trials in Europe and the USA. The trials showed protection of up to 90% against infection with ETEC. The trials also showed that the few people who received Travelan but were still affected by the ETEC had significantly less discomfort and diarrhoea episodes, compared to those who did not receive Travelan.